RA Session II
Taysha Gene Therapies (NASDAQ: TSHA)
RA Session II is the Founder, President and CEO of Taysha Gene Therapies (NASDAQ: TSHA). Mr. Session has nearly 20 years' experience life science industry primarily in corporate strategy, business development and financial roles. Previously, he served as Chief Business Officer of the gene therapy subsidiaries f Bridgebio (NASDAQ: BBIO), as well as SVP of Corporate Strategy and Business Development at Avexis (Sold to Novartis for $8.7B).
Education, Personal, and Fellowship
RA holds an MBA and an MSF from Texas A&M University at Commerce, College of Business and Technology and a BSBA from the University of North Carolina at Charlotte, Belk College of Business where he was a member of the NCAA ranked men's soccer team.
RA served his fellowship at PTC Therapeutics under the mentorship of company president Claudia Hirawat; he is a member of Class 19.